Publication 2025
431.
Schork A, Fritsche A, Schleicher ED, Peter A, Heni M, Stefan N, von Schwartzenberg RJ, Guthoff M, Mischak H, Siwy J, Birkenfeld AL, Wagner R.
Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics.
Metabolism. 2025 Jun;167:156174. Epub 2025 Feb 27.
430.
Frantzi M, Tymoszuk P, Salcher S, Gomez-Gomez E, Morillo AC, Melchior F, Blanca A, Mischak H, Vlahou A, Pircher A, Heidegger I.
Prediction of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy by Collagen Models Using Multiomic Profiles.
Eur Urol Oncol. 2025 Apr 30:S2588-9311(25)00094-X. Online ahead of print.
429.
Martin EM, Genovese F, Mischak H, Siwy J, Rupprecht H, Catanese L, Latosinska A.
Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients.
Proteomics. 2025 Apr 10:e202400354. Online ahead of print.
428.
Gregorich M, Kammer M, Mischak H, Heinze G.
Prediction Modeling With Many Correlated and Zero-Inflated Predictors: Assessing the Nonnegative Garrote Approach.
Stat Med. 2025 Apr;44(8-9):e70062.
427.
Mischak H, Schanstra JP, Vlahou A, Beige J.
Clinical Proteomics, Quo Vadis?
Proteomics 2025 Feb 9:e202400346.
426.
Yu YL, An DW, Chori BS, Kaleta BP, Mokwatsi G, Martens DS, Abiodun OO, Anya T, Łebek-Szatańska A, Yeh JS, Mels CMC, Latosinska A, Kruger R, Isiguzo G, Narkiewicz K, Shehu MN, Salazar M, Espeche W, Mujaj B, Brgulian-Hitij J, Olszanecka A, Wojciechowska W, Reyskens P, Rajzer M, Januszewicz A, Stolarz-Skrzypek K, Asayama K, Allegaert K, Verhamme P, Mischak H, Nawrot TS, Odili AN, Staessen JA; UPRIGHT-HTM investigators.
Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patients.
J Hypertens. 2025 Mar 1;43(3):481-491. Epub 2024 Nov 21.
425.
Aktas G, Keller F, Siwy J, Latosinska A, Mischak H, Mayor J, Clausen J, Wilhelmi M, Brauckmann V, Sehmisch S, Pacha TO.
Application of urinary peptide-biomarkers in trauma patients as a predictive tool for prognostic assessment, treatment and intervention timing.
Sci Rep. 2025 Jan 6;15(1):898.
424.
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group.
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
Diabetes Obes Metab. 2025 Jan;27(1):387-393. Epub 2024 Oct 28.
423.
Frantzi M, Morillo AC, Lendinez G, Blanca A, Lopez Ruiz D, Parada J, Heidegger I, Culig Z, Mavrogeorgis E, Beltran AL, Mora-Ortiz M, Carrasco-Valiente J, Mischak H, Medina RA, Campos Hernandez P, Gómez Gómez E.
Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI Pathway.
Pathobiology. 2025;92(2):99-108. Epub 2024 Nov 11.